Dow AgroSciences LLC, 9330 Zionsville Road, Indianapolis, IN 46268, USA.
Biotechnol J. 2010 Feb;5(2):172-82. doi: 10.1002/biot.200900217.
Substantial equivalence has become established as a foundation concept in the safety evaluation of transgenic crops. In the case of a food and feed crop, no single variety is considered the standard for safety or nutrition, so the substantial equivalence of transgenic crops is investigated relative to the array of commercial crop varieties with a history of safe consumption. Although used extensively in clinical medicine to compare new generic drugs with brand-name drugs, equivalence limits are shown to be a poor model for comparing transgenic crops with an array of reference crop varieties. We suggest an alternate model, also analogous to that used in clinical medicine, where reference intervals are constructed for a healthy heterogeneous population. Specifically, we advocate the use of distribution-free tolerance intervals calculated across a large amount of publicly available compositional data such as is found in the International Life Sciences Institute Crop Composition Database.
实质性等同已成为转基因作物安全评估的基础概念。对于粮食和饲料作物,没有单一品种被认为是安全或营养的标准,因此,相对于具有安全食用历史的商业作物品种,需要对转基因作物进行实质性等同性研究。虽然在临床医学中广泛用于比较新型仿制药与品牌药,但等效性限度被证明是比较转基因作物与一系列参照作物品种的不良模型。我们提出了另一种模型,也类似于临床医学中使用的模型,其中为健康的异质人群构建参考区间。具体来说,我们提倡使用分布自由的容忍区间,这些区间是通过大量公开可用的成分数据(如国际生命科学研究所作物成分数据库中发现的)计算得出的。